CAIRO — Kahira Pharmaceuticals and Chemical Industries reported a 24.5% rise in FY 2025/26 net profit to EGP552.5mn, with earnings growing faster than sales as the state-controlled drugmaker improved profitability toward the end of the financial year.
Revenue increased 21% to EGP2.51bn, from EGP 2.07 bn a year earlier, while net profit rose from EGP443.7mn. The faster earnings growth lifted the company’s implied net margin to about 22% from 21.4%.
Basic earnings per share increased to EGP37 from EGP 29.7, while pre-tax profit from continuing operations reached EGP697.5mn. Shareholders’ equity rose 23.7% to about EGP1.29bn.
Profit momentum strengthened toward year-end. Nine-month earnings had risen 17.3%, compared with the eventual 24.5% full-year increase, pointing to stronger profitability during the final quarter.
The board approved amended results following adjustments requested by Egypt’s Central Auditing Organization, which has separately raised observations concerning accounting controls, asset utilisation and delayed investment projects.
The performance provides a stronger financial test for Egypt’s wider programme to modernise state-owned pharmaceutical manufacturing. Sustained gains will depend increasingly on whether Kahira can convert upgraded production capacity and higher sales into stronger productivity, tighter capital discipline and durable returns on industrial investment.
Related news:
Europe Tests AI Alternative to Palantir’s Battlefield System
How Digital Health Is Reshaping Healthcare Delivery in Egypt
Read also:
AI Is Advancing Faster Than Governments Can Build the Rules Around It
Nine Projects averaging $1bn investments granted golden license for strategic investment projects
